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Microelectromechanical systems (MEMS) is also called micro-
fabricated devices, lab-on-chip, microsystems, micro-total
analysis systems (micro TAS), which existed for more than
30 years, with several applications attaining commercial and/
or scientiﬁc success. Commercially, high-throughput, low-
volume-consumption technologies such as whole genome
sequencing projects and drug discovery have created a need
for these devices. Scientiﬁcally, the ability to design and con-
trol experiments at the micrometer scale has attracted the
interest of biologists, who have started devising fundamental
studies using this technology (Joel et al., 1999).
MEMS techniques were originally developed in the micro-
electronics industry. Microelectronic process engineering is a
discipline that developed due to the rapid growth of the inte-
grated circuit (IC) industry. Traditionally, microelectro-
mechanical systems (MEMS) have been used to produce func-
tional devices on the micron scale, such as sensors, switches,
ﬁlters, and gears, from silicon, the dominant material used
throughout the IC industry. Microelectromechanical system
(MEMS) techniques have enabled development of miniatur-
ized diagnostic tools and high throughput screening assays
for drug discovery and tissue engineering (Sant et al., 2011).
Although in their embryonic, microfabrication technologies
are being explored for drug delivery.
The review summarized detail account of how to prepare
MEMS device, various strategies of it and application of
MEMS in drug delivery and in analytical methods.2. Strategies for fabricating patterned MEMS
There are four basic processes are used for the fabrication of
MEMS. The ﬁrst is photolithography or soft lithography,
which transfers a pattern into a material. The second is thinﬁlm growth/deposition, in which thin ﬁlms (usually on the or-
der of micrometers in thickness) are grown or deposited onto a
substrate. Etching, the third kind of process, creates features
by selectively removing materials (either thin ﬁlms or sub-
strate) in deﬁned patterns. The ﬁnal kind of process is bonding,
where two substrates (often structured and with thin ﬁlms) are
bonded together.
Photolithography process depicted in Fig. 1 is used to
transfer a pattern envisioned by the designer into a material.
A pattern, drawn with a computer assisted design (CAD) pro-
gram (Fig. 1a), is transferred onto a mask (Fig. 1b). The mask
is a glass plate that has on its surface a photo deﬁnable opaque
material (usually chrome) in the desired pattern and is typically
prepared by a mask vendor. If the features and tolerances in
the pattern are relatively large (>20 lm), then one can use a
simpler mask-making process (Duffy et al., 1998). After mask
making, the pattern transfer begins when the substrate
(Fig. 1c) is spin-coated with photoresist (Fig. 1d), a photosen-
sitive organic polymer. The substrate and mask are brought
into contact, and UV light is shown through the mask and
onto the photoresist (Fig. 1e). Photoresist under the transpar-
ent portions of the mask will be exposed, causing it to become
soluble in a developing solution. This is known as a positive
photoresist (negative photoresist gives the inverse pattern).
The wafer and mask are separated, and the exposed photore-
sist is removed in the developing solution (Fig. 1f). The photo-
resist can now be used as a protective mask to transfer the
pattern into the underlying material via etching. When ﬁn-
ished, the photoresist is removed.
Soft lithography is the collective name for a set of litho-
graphic techniques Replica molding (REM), Microcontact
printing (lCP), Micromolding in capillaries (MIMIC),
Microtransfer molding (lTM), Solvent-assisted micromolding
(SAMIM), and Nearﬁeld conformal photolithography using
an elastomeric phase shifting masks that has been developed
as an alternative to photolithography and a replication
Figure 1 Conﬁguration allocation with photolithography.
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These techniques use a patterned elastomer (usually PDMS)
as the mold, stamp, or mask to generate or transfer the
pattern. Soft lithography offers immediate advantages over
photolithography and other conventional microfabrication
techniques for applications in which patterning of nonplanar
substrates, unusual materials, or large area patterning is the
major concerns. It is especially promising for microfabrication
of relatively simple, single-layer structures for uses in cell cul-
ture, as sensors, as microanalytical systems, in MEMS, and in
applied optics (Xia et al., 1999).
Microcontact printing (lCP) uses a soft polymeric stamp,
usually made of PDMS, which has been formed by molding
to a master made by conventional microfabrication. The stamp
is ‘‘inked’’ with self-assembled monolayers (SAMs) of alkan-
ethiols or alkylsilanes and placed on a gold- or silicon diox-
ide-coated surface, respectively. This transfers the molecules
from the stamp to the substrate, where they form a self-assem-
bled monolayer in the same pattern as the stamp. These pat-
terned self-assembled monolayers can then be used as resists
for etching or as passivation layers to prevent deposition. This
method of pattern transfer is advantageous when working with
non-cleanroom compatible materials or chemicals, or nonpla-
nar substrates, although unresolved issues exist with multilevel
pattern registration (Whitesides and Xia, 1998).
2.1. Substrate materials
Silicon is the most common material in microfabrication, ow-
ing to its role in the fabrication of integrated circuits and its
excellent electrical properties, silicon also possesses outstand-
ing mechanical properties, enabling the design of microelectro-
mechanical structures (Petersen, 1982). For biological or
medical microsystems, silicon may not be the material of
choice (Joel et al., 1999). It is not optically transparent, pre-
venting the use of transmission microscopy, and its cost can
potentially be too large for disposable devices.
Glass is also used as substrate material in microfabrication
although the range of micromachining processes for glass is
less extensive than for silicon, glass provides some unique fea-
tures, most notably optical transparency. Glass wafers are
available in many different compositions and sizes. Two
important examples are fused silica wafers and borosilicate
wafers. Fused silica wafers are pure amorphous silicon
dioxide (SiO2). They can withstand high temperatures(Tsoftening = 1580 C), are optically transparent down to short
wavelengths, and have very low autoﬂuorescence. Borosilicate
wafers, of which the most common is Pyrexª (Corning 7740),
are much less expensive than fused silica (and can be less
expensive than silicon). They can be easily bonded to silicon
but cannot be exposed to the high temperatures needed for
some thin-ﬁlm depositions and have higher autoﬂuorescence
than fused silica (Joel et al., 1999).
Plastic is often the least expensive substrate material. The
availability of mass production processes (e.g. injection mold-
ing, embossing) that can be extended to the microscale means
that plastic devices can be extremely inexpensive to produce in
volume. This allows for disposable devices, which minimizes is-
sues of sterilization, clogging, and drift. For these reasons, a
majority of commercial enterprises are using plastic microde-
vices, especially for disposable clinical applications. Most de-
vices to date have been separation channels for capillary
electrophoresis. In addition, the softness of plastics can mean
poor dimensional tolerance and stability, and autoﬂuorescence
is often a problem (Joel et al., 1999).
2.2. Thin-ﬁlm growth/deposition
Thin ﬁlms are used for a variety of different purposes in micro-
structures masking materials, structural materials, sacriﬁcial
materials, and electrical devices, to name a few. They are
formed by either chemical reaction driven processes or physi-
cal processes (Joel et al., 1999).
Chemical vapour deposition is a process that produces thin
metal, ceramic, or compound ﬁlms, through thermal oxidation
in a gas chamber at an elevated temperature. Within the cham-
ber the substrate interacts, at temperatures between 800 and
2000 C and pressures between millitorrs and torrs, with vola-
tile precursors that react and decompose on the substrate a
ﬁlm of a metal (e.g. Al, Ta, Ti, Pt.), ceramic (e.g. Si3N4,
B2O3, BN) or compound (Effenhauser et al., 1997). The gas
mixture typically consists of reducing gas, like hydrogen
(H2), inert gases like nitrogen (N2) or argon (Ar), and reactive
gases such as metal halides and hydrocarbons. A typical chem-
ical reaction sequence includes pyrolysis, reduction, oxidation,
hydrolysis and co-reduction. For example, silicon nitride
(Si3N4) can be deposited by means of reaction of dichlorosi-
lane gas (SiCl2H2) with ammonia gas (NH4) at temperatures
between 700 and 800 C (Athanasios, 2011). The volatile by-
products can be blown away from the reaction chamber and
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vapour deposition can also be plasma enhanced a method that
functionalizes surfaces and is effective in depositing hydropho-
bic ﬁlms on wafers.
Physical vapour deposition, such as sputtering or evapora-
tion, is used to deposit thin ﬁlms, layer by layer, onto sub-
strates. This method employs mechanical or thermodynamic
means for producing thin ﬁlms and requires low-pressure
vaporized environment to function (Athanasios, 2011).
Adsorption is a chemical deposition method that exploits
hydrophilic head groups of self-assembled monolayers of, for
example, hydrophobic trichlorosilanes (Cl3SiCnH2n+1), or thi-
ols (HSCnH2n+1), which offer spontaneous binding on glass or
metal surfaces (Schreiber, 2000).
Ion beam enhanced deposition inﬂuences the energy and
charge states of the gas in the vapour phase and allows control
over the energy state and crystallographic and stoichiometric
form of the deposited ﬁlms (Athanasios, 2011).
Deposition and patterning of biomolecules, most com-
monly proteins, are quite important in biological applications
of microfabrication. Three predominant methods to accom-
plish this have been reported (Blawas and Reichert, 1998).
The ﬁrst method, protein adsorption, relies on physical
adsorption of proteins in solution onto a substrate. The pat-
terning is achieved either by dissolution of protein covered
photoresist patterns or by constraining where the protein
solution ﬂows via microchannels (Blawas and Reichert,
1998; Delamarche et al., 1997; Folch and Toner, 1998). The
co-cultures were made by patterning extracellular-matrix
proteins in the former manner. The second method of biomo-
lecular patterning is using photochemistry, where UV light
shown through a patterned mask is used to activate or
deactivate chemical species. The ﬁnal method uses patterned
self-assembled monolayers to selectively inhibit or allow
protein attachment (Whitesides and Xia, 1998; Blawas and
Reichert, 1998).Figure 2 Overview of (left) isotropic and (right) anisotropic
etching, anisotropic etching by (middle) dry etching or by (right)
wet anisotropic etching.2.3. Etching
In microfabrication technology, patterning is the transfer of
outlines of features (which deﬁne microchannels, microelec-
trodes, or other components) on the top of a substrate by
means of ultraviolet illumination via a photomask. The photo-
mask consists of a chromium layer where only part of it is
transparent to the light. Photolithography is the method for
producing structures by exposing photosensitive resists to
ultraviolet light via successive photomasks and then removing
the exposed areas of the photoresist in a development process.
The photosensitive resist is a polymer, usually epoxy, which is
sensitive to ultraviolet light. When the ultraviolet exposes spe-
ciﬁc areas, the photoresist polymerizes and resists to etchers.
This replicates the patterns onto the photoresist ﬁlm. The ex-
posed areas of the resist ﬁlm are being attacked by the devel-
oper and consequently removed. The unexposed areas
remain resistant to the action of the etchant. The structure
can be revealed after etching the exposed areas. Every wafer
substrate may undergo many sequential etching cycles before
completes (Athanasios, 2011).
Etching can be divided into wet (via liquid chemicals) or
dry (via gas-phase chemistry) etching. Either method can lead
to isotropic or anisotropic etching. Isotropic etching etches inall directions equally, leading to mask undercutting and a
rounded etch proﬁle (Fig. 2, left). Anisotropic etching is direc-
tional (Fig. 2, middle, right) and is either chemically or physi-
cally (sputter etching) induced. In general, wet etching is more
selective than dry etching, whereas anisotropic etches are more
common with dry etching. Chemical etches are more selective
than physical etches but amenable to fewer materials. The aim
is to ﬁnd a complementary set of materials and etchants, thus
allowing selective pattern transfer (Joel et al., 1999).
Etching can be distinguished as two etching processes, wet
etching and dry etching.
Wet chemical etching is widely used for producing micro-
electrodes and microﬂuidic channels on substrates. The wet
etching requires acids, bases or mixtures to dissolve metals, sil-
icon or glass, by immersing the substrate into the etching solu-
tion. For instance, gold can be etched using iodine solution.
The etching can be isotropic or anisotropic. As an example, sil-
icon Æ100æ can be etched isotropically with HF–HNO3, which
produces rectangular curved grooves by means of thermally
grown SiO2 mask. KOH can etch Si Æ100æ or Si Æ110æ aniso-
tropically; the etchant should be selected carefully in order to
have the etching rate of the masks considerably lower than that
of the removable material. The ﬁnal step in a wet etching pro-
cess is to remove the resist by washing it away with an organic
solvent (Athanasios, 2011).
Dry etching involves reactive ion etching with plasma,
where the substrate is placed into a plasma chamber where a
gas mixture is introduced and is ionized. The ionized gas mix-
ture reacts with the surface of the substrate to be etched. As the
ionized gas is highly energized, it removes the matter from the
substrate. Xenon diﬂuoride (XeF2) is a dry vapour phase iso-
tropic etcher for silicon. SF6 in high-density plasma provides
anisotropic high-aspect-ratio etching for silicon (Athanasios,
2011).
2.4. Bonding
In many processes, there will be a desire to bond two sub-
strates (possibly with thin ﬁlms) together to form a hermetic
seal. A common example is the bonding of a glass capping wa-
fer to a structured silicon wafer to form an optically accessible
sealed system. Many technologies have been developed to
bond different materials together, either with or without inter-
mediary layers (Schmidt, 1998).
Anodic bonding can fuse silicon or glass plates. The two
opposing plates must come in contact with each other, in heat,
with a high voltage applied across a conductive layer (200 nm
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ately, that causes diffusion of ions, which eventually fuses
the two plates electrostatically. Anodic bonding conditions
vary between 200 and 1500 V, at 200–450 C (Athanasios,
2011).
Thermal bonding can fuse glass or polymer plates. Thermal
bonding is performed on coated with methylsilses-quioxane, or
polysiloxane, surfaces at temperatures 150–210 C. Annealing
for some hours in low vacuum produces bonds that withstand
hundreds of N/cm2. Rapid glass bonding requires hot pressure
at 570 C for 10 min under 4.7 N/mm2 (Athanasios, 2011).
Photopolymer adhesives can bond any type of rigid sub-
strates. This method is more tolerant for uneven surfaces since
it provides a compressible cushioning layer that seals the chip.
The adhesive layer can be benzocyclobutene (C8H8) or UV-
curable resins of micrometer thickness. It is possible to heat
and separate the plates apart and rebond (Athanasios, 2011).
Other bonding techniques abound. To join two metal layers
together, one can use eutectic or thermocompression bonding
(Schmidt, 1998). Substrates can be bonded with adhesives,
whereas plastics can be bonded by heating them to above their
glass transition temperature and then compressing them
(Martynova et al., 1997). PDMS can be reversibly hermetically
bonded to glass or to itself by simple contact (Effenhauser
et al., 1997) and can be irreversibly bonded to itself by oxidiz-
ing two pieces and placing them together (Duffy et al., 1998).3. Application of MEMS in drug delivery
Biomedical microelectromechanical systems (BioMEMS)
based drug delivery devices have become commercially feasible
over the past several years due to converging technologies and
regulatory accommodation. MEMS technology has been ap-
plied to the successful development of a variety of health care
related products. Although research on microfabricated de-
vices for biomedical applications, particularly in diagnostics,
has rapidly expanded in recent years, relatively few researchers
have concentrated on therapeutic applications of microfabrica-
tion technology, such as drug delivery. Combination products
constructed using MEMS technology offer revolutionary
opportunities to address unmet medical needs related to dos-
ing. These products have the potential to completely control
drug release, meeting requirements for on-demand pulsatile
or adjustable continuous administration for extended periods,
programmable dosing, sequential dose delivery and diagnostic
feedback dispensing. MEMS technologies are signiﬁcantly
developed in recent years, providing a multidisciplinary foun-
dation for developing integrated therapeutic systems. If
small-scale biosensor and drug reservoir units are combined
and implanted, a wireless integrated system can regulate drug
release, receive sensor feedback, and transmit updates. For
example, an ‘‘artiﬁcial pancreas’’ implementation of an inte-
grated therapeutic system would improve diabetes manage-
ment. The tools of microfabrication technology, information
science, and systems biology are being combined to design
increasingly sophisticated drug delivery systems that promise
to signiﬁcantly improve medical care. Several review articles
are available regarding trends in microfabricated systems for
drug delivery, with a few examples outlined here (Ainslie and
Desai, 2008; Hilt and Peppas, 2005; LaVan et al., 2003; Staples
et al., 2006; Tao and Desai, 2003).3.1. Programable
Microfabrication technology has been used to fabricate pro-
grammable devices as a new class of controlled release systems
for drug delivery. These devices are particularly intriguing due
to their small size, potential for integration with microelectron-
ics and their ability to store and release chemicals on demand
(Santini et al., 2000). The ﬁrst experimental demonstration of a
microchip with potential application in drug delivery was de-
scribed by Santini et al. The ultimate goal of this approach
is to develop a microfabricated device devoid of moving parts,
but with the ability to store and release multiple chemical sub-
stances (Santini et al., 2000, 1999). Drugs stored within reser-
voirs were sealed either with active or passive coatings. For
example, in the original work the reservoirs were sealed with
a thin layer of gold and released upon application of an ap-
plied electric potential that dissolved the coating. Subsequent
version also included fully degradable polymeric systems with
plastic seals.
3.2. Particulate systems
As their scale decreases, microfabricated devices can be deliv-
ered by ingestion (<1 mm), intra-tissue injection (<200 lm),
inhalation (<100 lm) or released into circulation (<10 lm)
(LaVan et al., 2003). Microfabrication methods, because of
their ability to control microarchitecture and feature size, have
been used successfully to develop novel nano/microparticles
for applications in drug delivery. Silicon particles have been
used as multistage drug delivery systems (Tasciotti et al.,
2008) and for intravenous delivery (Martin et al., 2005).
Several methods, including soft lithography, particle replica-
tion in non-wetting templates (PRINT), hydrogel templating,
imprint lithography, and in situ photo polymerization in
microﬂuidic channels have been developed to prepare homoge-
neous polymeric particles. Microstructures with complex
geometries can inﬂuence anisotropic interactions with biomol-
ecules and cells (Sant et al., 2011).
4. Oral drug delivery by BioMEMS
BioMEMS is the emerging approach in the ﬁeld of oral drug
delivery systems. They have signiﬁcant potential to overcome
some of the barriers of oral drug delivery through fabrication
of asymmetrical devices with precise control over size and
shape. Apart from drug delivery devices, microfabrication ap-
proaches can also enhance the ﬁeld of oral drug delivery by
designing biomimetic in vitro GI tract model systems that
can aid in better prediction of drug absorption in vivo. Thus
MEMS technique is used in the development of oral drug
delivery system and in vitro cell culture models that can be
used to evaluate the drug delivery efﬁcacy (Sant et al., 2011).
Microfabrication also offers great opportunities to enhance
the oral delivery of pharmaceuticals by allowing for precise
control over shape, size, and geometry of delivery devices.
Microfabricated devices can also increase drug loading
capacities and provide better control over drug release. One
approach for inducing greater levels of absorption and stabil-
ity at the intestinal epithelium is the use of a multi-layered
patch system. Patches are designed with layers of thin, ﬂexible
membranes: an impermeable backing, a drug reservoir, a
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is applied, the drug begins to ﬂow through the skin into the
bloodstream at a rate regulated by the membrane, pre-
programmed to keep the drug at an effective level. These
properties are ideal for oral dosage forms intended for delivery
to the intestinal mucosa. Microfabricated patch systems
designed for oral drug delivery are capable of three main
functions: (i) bioadhesive properties for retention of the dosage
form, (ii) release drug in a controlled fashion, and (iii)
provide unidirectional release toward the intestinal epithelium
(Tao and Desai, 2005a,b,c).
4.1. Micropatch
The size of orally delivered particles has a great impact on their
transit through the GI tract. Larger particles can get trapped in
the mucus layer protecting the epithelium, resulting a relatively
short residence time. Certain types of smaller Micro- and
Nano-scale particles are known to permeate the epithelium
(Tao and Desai, 2005a,b,c), but the uptake is largely restricted
to Peyer’s patches, which take up a small fraction of the brush
border and lead to lymphoid tissue. This pathway carries the
risk of toxic accumulation and poor bio-distribution.
Microfabricated patch systems are alternative to standard
particulate delivery systems, such as microspheres. They are
designed small enough to travel in between intestinal villi,
maximizing the large absorptive surface area of the intestinal
folds, but wide enough to prevent cell uptake. In contrast to
particulate systems, micropatches are designed ﬂat and thin
to maximize contact area with the intestinal lining. At the same
time, this ﬂat design minimizes the side areas exposed to the
constant ﬂow of liquids through the intestine. The devices
can be microfabricated to incorporate single or multiple drug
reservoirs which can be loaded with any number of drugs/bio-
molecules of interest. These reservoirs, unlike multidirectional
release from a spherical delivery system, allow for unidirec-
tional release of the drug. Furthermore, regions of the device
can be surface modiﬁed in order to incorporate cell targeting
mechanisms which localize the vehicle at a speciﬁc site of ac-
tion. Modiﬁcation of microspheres is performed uniformly
over the entire surface area, which increases instability and
may induce rolling when exposed to ﬂow (Sant et al., 2011).
However, selective surface modiﬁcation on only the reservoir
side allows micropatches to stably anchor in an orientation
which permits the released drug to follow the shortest diffu-
sional pathway toward the intestinal epithelium. Fabrication
processes for creating oral micropatches have been developed
based on standard MEMS fabrication techniques including
photolithography, etching, and thin ﬁlm deposition, as well
as soft lithography (Tao and Desai, 2005a,b,c).
Standard materials such as porous silicon and silicon oxide
have been successfully used for microfabrication based drug
delivery systems. Although silicon and glass are the materials
of choice for electronic and mechanical devices, it is not clear
if these materials are necessarily appropriate for all applica-
tions in biology and medicine (Quake and Scherer, 2000).
Polymers allow for shorter fabrication times and potential
large scale fabrication of complex drug delivery vehicles. In
one such demonstration, poly(methyl methacrylate) (PMMA)
microdevices were fabricated using an off-wafer process.
Microdevices were also fabricated from SU-8, a chemicallyampliﬁed; epoxy based negative photoresist typically used for
producing ultra-thick resist layers. The use of SU-8 as a device
material eliminates the need of a secondary patterning material
and the dry etch procedure. Instead, multi-level processing can
be used to create features in multiple layers. Repeated, aligned
photolithography was used to deﬁne the backing, reservoir,
and supplementary feature layers (Ainslie et al., 2008, 2005).
Asymmetrical microparticles were also fabricated from biode-
gradable polymers poly(DL-lactide-co-glycolide) (PLGA) and
gelatin using soft lithographic techniques. In this manner, sev-
eral batches of asymmetrical microparticles may be generated
from a single master. The height of the resulting devices is
determined by the height of the features in the PDMS master
and the concentration of polymer in solution. Lateral resolu-
tion is determined by the features of the PDMS master and
the solvents used. Guan et al. were able to combine methods
of dip-coating, microcontact hot-printing and soft lithography
to produce microdevices containing single-reservoir and multi-
ple-reservoir systems as well as sustained release microcapsule
depots in PLGA (Fig. 3A–C).
Micropatch systems offer some advantages in drug loading
over conventional solid dosage forms. They can contain reser-
voirs which can be loaded by microinjection with Pico to
Nano-liters of a polymeric solution. Water quickly evaporates
from these reservoirs leaving behind the drug contained in a
timed-release polymer plug. Intimate contact between the
micropatch and intestinal epithelium would provide a short
diffusion distance, potentially negating the need for excipients
to aid in dissolution. Using a speciﬁc type of polymer reservoir
would predetermine the time and rate of release of drug from
the reservoir; for example, a hydrogel that swells in response to
a speciﬁc pH, solvent or temperature or a polymer with a
known dissolution rate. Different polymers with various disso-
lution rates could then be used in separate reservoirs to obtain
controlled release of several compounds. By capitalizing on
surface-liquid interactions, it is also possible to utilize discon-
tinuous de-wetting as a method for bulk ﬁlling of reservoirs
(Guan et al., 2007).
Micropatch reservoirs can also be ﬁlled using photolithog-
raphy. For example, after microdevice development, a photo-
sensitive hydrogel precursor solution, consisting of a
crosslinker, photoinitiator, poly(ethylene glycol) dimethacry-
late (PEGDMA) and drug, can be spun into the empty reser-
voirs. Using a mask aligner, only the hydrogel within the
reservoir is exposed to UV light and subsequently developed
in water and isopropanol. Using repeated application and
crosslinking, microdevice reservoirs can be loaded with mul-
ti-layered hydrogels for sequential delivery of therapeutics
(Ainslie et al., 2008, 2005). In the case of soft lithographic
methods for fabrication of particles, drugs may be added to
the prepolymer solution and incorporated into the device dur-
ing the transfer process (Tao and Desai, 2005a,b,c).
4.2. Bioadhesion
As an alternate way to overcome short gut residence times and
poor mucosal contact, increasing interest has been placed on
bioadhesive systems that can delay the transit and prolong
their residence at a speciﬁc site of delivery, thus enhancing
the drug absorption process (Huang et al., 2000; Serra et al.,
2009). These mucoadhesive devices can protect the drug during
Figure 3 (A) Single-reservoir microdevices released in water showing asymmetrical plate-like geometry with ring-shapped microwell in
the center for drug loading; (B) multiple reservoir microdevices released in water, containing 14 closed reservoir surrounded by a number
of open reservoir; (C) microcapsules made from PLGA as sustained release depots; (D) self-folding polymeric microdevice with enhanced
mucoadhesion for transmucosal drug delivery; (E) foled microdevices grabbing onto pig intestinal mucosa with stable adhesion even after
water rinsing (ﬁgure adapted from Guan et al., 2007).
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to the delivery site. This in turn increases the drug concentra-
tion gradient due to intense contact. The general concepts and
mechanisms of mucoadhesion have been reviewed in detail
(Serra et al., 2009). In general, bioadhesion can be achieved
through chemical or physical approaches.
In chemical bioadhesion approach the use of adhesion pro-
moters such as linear or tethered polymer chains to promote
bioadhesion during oral drug delivery. Mucoadhesion depends
largely on the structure of the synthetic polymers used in con-
trolled release applications and has been reviewed by Serra
et al. Another strategy utilizing immobilization of lectin as tar-
geting molecules for enhanced adhesion and speciﬁcity to
intestinal epithelial models has been previously described
(Lehr, 2000; Naisbett and Woodley, 1990; Wood et al.,
2006). Post-fabrication chemical modiﬁcation may be per-
formed to immobilize bioactive targeting molecules to the sur-
face of microdevices (Ainslie et al., 2005).
In vitro studies were performed using the Caco-2 cell line to
measure the cytoadhesive properties of lectin-conjugated mic-
rodevices. Tomato lectin modiﬁed microdevices and micro-
spheres were also studied in order to compare the effect of a
tailored microdevice shape versus a traditional spherical shape
on adhesion stability. It was found that the percent of microde-
vices remained consistently bound (68% of total applied)
over consecutive washes while microspheres signiﬁcantly de-
creased to approximately 17% (Tao and Desai, 2005a,b,c).
Although microspheres have a larger surface area, or more
importantly a larger lectin modiﬁed surface area, than the
micropatch systems, microspheres appeared to be less stable
when subjected to consecutive removal. The stability may be
in part associated with the small fraction of the surface area
which is directly in contact and anchoring to the cell mono-
layer at any given time. This suggests that the larger modiﬁed
contact area of the ﬂat micropatch device may provide a more
stable interface. Additionally, studies have shown that these
micropatch systems promote stable adhesion in the presence
of mucin (Tao and Desai, 2005a,b,c), as well as under shear
ﬂow conditions (Ainslie et al., 2005).
By using physical approach for bioadhesion microdevice
bodies can be designed to contain precisely shaped micronee-
dles and microposts. These features may allow for the particle
to more ﬁrmly adhere to the mucosa, potentially increasing
drug permeability (Sant et al., 2011).
Microneedle systems were originally developed as an ap-
proach to enhance the poor permeability of the skin by creat-
ing microscale conduits for transport across the stratumcorneum for transdermal drug delivery (Henry et al., 1998).
The microfabrication of microneedles those are long and ro-
bust enough to penetrate this layer of skin, but short enough
to avoid stimulating nerves, has the potential to make trans-
dermal delivery of drugs more effective (Henry et al., 1998;
McAllister et al., 2000), microneedle platforms have
been fabricated in silicon, and also transferred into biodegrad-
able carboxymethylcellulose, amylopectin, poly(lactic acid),
poly(glycolic acid), and PLGA (Lee et al., 2008; Park et al.,
2005). Tapered, needle-like structures have also been scaled
down into the submicron range to provide adhesion and drug
delivery in wet environments for potential applications in sur-
gical, wound, and internal bandage systems (Mahdavi et al.,
2008). Microneedles, in combination with infusion methods
such as pressurized reservoirs and electrically controlled sys-
tems, have also been utilized for drug delivery. (Martanto
et al., 2006; Roxhed et al., 2008). Furthermore, by modifying
needle dimension and design to incorporate multiple channels
and ports, optimized micro hypodermic needles and microp-
robes have also been developed for cellular, local tissue, or sys-
temic delivery (McAllister et al., 2000).
The microneedle/micropost design principles can also be
applied to oral drug delivery to increase the retention time of
the microfabricated devices in the GIT. Using microfabrica-
tion techniques, oral microdevices can be designed to contain
precisely shaped microposts/microneedles. These features
may penetrate the mucus layer leading to anchorage of the par-
ticles/microdevices. For example, Guan et al. used a similar
approach to fabricate a bilayered system of a poly(EGMA-
co-EGDMA) and crosslinked chitosan microparticles with
self-folding arms. It is expected that by penetrating into the
mucus layer, the arms may anchor microparticles, providing
increased resistance to surface erosion of the mucus layer
(Guan et al., 2007). This mechanism may also provide a means
to ‘‘grab’’ the intestinal villi, also potentially leading to a long-
er retention time of the device (Fig. 3D and E). In addition, the
presence of microposts on oral microdevices may shed mucosa
to increase the uptake of compounds into the blood vessels of
the submucosa. Combined with the current chemically driven
targeting mechanism, these microposts may provide a mechan-
ically driven controlled release feature (Tao and Desai,
2005a,b,c).
Another physical method to enhance bioadhesion is the use
of a particularly promising class of gecko-inspired or Nano
structure based adhesives. Under Nano-adhesive conditions,
as the number of adhesive elements per surface area increases,
the surface area to volume ratio increases and van der Waals
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microvilli present on the surface of the mucosal epithelia dra-
matically increase its surface area. Therefore, by creating a
nanostructured microdevice to target the microvilli coated
intestinal epithelium, it may be possible to generate strong bio-
adhesive forces due to geometric features alone. A standard
vapour ‘‘liquid–solid’’ method for synthesizing silicon nano-
wires on ﬂat wafer surfaces has been used in order to achieve
growth of size-speciﬁc nanowires on microdevice surfaces
(Fischer et al., 2009). Nanowire-coated devices were found to
adhere to Caco-2 cells at a frequency of ﬁve times greater than
non-coated devices under static conditions, and when tested
under ﬂow conditions, a median survival shear (the shear at
which 50% of the devices detach) of 9.15 dyn/cm2 was re-
ported. Additionally, devices both chemically (tomato lectin)
and physically (nanowire) modiﬁed for bioadhesion adhered
as well or slightly better than unmodiﬁed devices under static
conditions. However, under ﬂow conditions and in the pres-
ence of mucin, these dually modiﬁed devices were found to
be disadvantageous in terms of adhesion, with a median sur-
vival shear of 3.60 dyn/cm2. As lectins bind to both cells and
mucus, adding a mucin layer introduces competition between
these elements for binding to the lectin-modiﬁed nanowires,
which may explain reduced adhesion. Therefore, geometry-
based adhesion may offer distinct advantages over mucoadhe-
sive chemistry in terms of mucosal tissue adhesion.
5. Microfabricated in vitro models
Development of physiologically relevant three-dimensional
(3D) in vitro models is another area where microfabrication
can advance the ﬁeld of oral drug delivery. The drug develop-
ment process is a long and expensive process with only one
out of ten drug candidates in clinical trial reaching ﬁnal
FDA approval stage. The number of new molecular entities
that are approved by the FDA is also declining with 53
approved in 1996 and only 19 approved in 2010 (Mullard,
2011). The main reason for this low success rate is poor
prediction of drug efﬁcacy and toxicity in preclinical testing.
The current drug testing paradigm is based on 2D cell
monolayers and in vivo animal models before clinical trials
in humans. Although 2D cell monolayer-based assays are
routinely used for drug efﬁcacy and toxicity testing, such
systems often fail to recapitulate microenvironmental context
and in vivo biological complexity. Such systems are static and
do not mimic the exchange of metabolites between the
tissues, physiological shear stress, ﬂuid ﬂow dynamics as
experienced by cells in vivo (Park and Shuler, 2003). In vivo
animal models allow testing drug distribution, efﬁcacy and
toxicity under physiological conditions; however, there are
differences in animal and human physiology making extrapo-
lation of animal data to human difﬁcult. Animal studies are
also expensive, time consuming and ethically controversial.
Better in vitro model systems are necessary to accurately
predict drug efﬁcacy and toxicity. Microfabrication ap-
proaches have been proposed recently to develop physiologi-
cally relevant, in vitro 3D tissue models to reduce or replace
animal studies. These include various strategies such as
‘organ-on-a-chip’ (Moraes et al., 2011), ‘body-on-a-chip’
(Esch et al., 2011), ‘lung-on-a-chip’ (Huh et al., 2010) and
‘perfused multi-well liver tissue’ (Domansky et al., 2010).Conventional approaches to study drug absorption across
the intestinal mucosa are classiﬁed into in vivo, in situ and
in vitro models and have been reviewed elsewhere. The most
accepted and widely used in vitro absorption model consists
of Caco-2 cells seeded on a polycarbonate membrane in a
transwell device (Peppas and Carr, 2009). When cultured as
a monolayer, Caco-2 cells differentiate to form brush border
microvilli on the upper side of the monolayer and contain both
tight junctions and brush border associated enzymes. In this
model, test compounds are added on the apical side of the
Caco-2 cell monolayer, and compounds penetrating the cell
are monitored at the basolateral side of the monolayer.
Although used successfully to model oral drug absorption
(Yazdanian et al., 1998), this model still has limitations. For
example, low permeabilities have been observed in vitro com-
pared to in vivo data for the drugs that are transported
through paracellular transport route. Similarly, compounds
with low solubility/dissolution may have less absorption than
that predicted by the Caco-2 system since oral absorption
may be limited by low solubility. In addition, Caco-2 monolay-
ers are planar in geometry, and do not accurately represent the
brush border topography. Also, the use of a static monocul-
ture neglects the inﬂuence of mucus-secreting goblet cells,
and peristalsis on drug absorption. Furthermore, these mono-
layers cannot be used to predict the bioavailability of com-
pounds susceptible to hepatic ﬁrst pass clearance.
Microfabricated devices can potentially better model the GI
surface topography and can also be used to better control the
mechanics of cell–cell and cell–substrate interactions. Current
efforts in this ﬁeld can be divided into three approaches: (i)
engineered intestinal tissues; (ii) microﬂuidic-based approaches
and (iii) microscale cell culture analogs (lCCA).
5.1. Engineered intestinal tissues
The small intestinal epithelium consists of an epithelial mono-
layer of enterocytes, goblet cells, and Peyer’s patches resting on
a basement membrane. The absorptive surface area is
enhanced through the topographical arrangement of this
monolayer into ﬁnger-like projections (villi) and well-like
invaginations (crypts). In addition to enhancing surface area,
this spatial arrangement also dictates cell behavior. Wang
et al. used simple microfabrication approaches to create biomi-
metic crypt-like microarchitecture on polymer substrates
(Wang et al., 2009). Caco-2 cells seeded on such substrates
showed higher metabolic activity and lower alkaline phospha-
tase activity compared to the ﬂat substrates signifying inﬂu-
ence of topography on cell phenotype. In a follow-up study,
authors patterned type I collagen membrane using soft lithog-
raphy to study the synergistic effect of crypt-like topography
and extracellular matrix (ECM) proteins (ﬁbronectin and lam-
inin) on Caco-2 adhesion, proliferation, differentiation and
tight junction formation (Wang et al., 2010). It was found that
crypt-like topography had short term effects on cell phenotype
whereas substrate chemistry (ECMprotein coating) had more
prominent and long term effects on intestinal epithelial cell
behaviors. Insight from such studies can be useful in develop-
ing biomimetic in vitro intestinal models for drug absorption.
Gunawan et al. created immobilized physiological protein
gradients (laminin and collagen type I) similar to those found
in small intestinal crypts using microﬂuidic gradient generator.
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differentiation marker) and proliferating cell nuclear antigen
(PCNA; proliferative cells), markers that are linked to the cell
cycle progression, when intestinal epithelial cells were cultured
on immobilized counter-gradients of laminin and collagen I.
Such studies are necessary to understand the role of various
ECM proteins on the intestinal epithelial renewal along the
crypt–villus axis (Gunawan et al., 2005).
Another emerging approach to engineer biomimetic GI
tract models is the use of hydrogels. Hydrogels have attracted
great attention for 3D cell cultures since they mimic the ECM
and can be easily modiﬁed to generate tailored microenviron-
ments (Slaughter et al., 2009; Peppas et al., 2000). Addition-
ally, hydrogels are amenable to various micromolding and
soft lithographic techniques for drug delivery (Guan et al.,
2007) as well as tissue engineering applications (Aubin et al.,
2010).
Recently, Sung et al. developed a biomimetic GI tract mod-
el using laser ablation combined with sacriﬁcial molding in
microscale collagen hydrogels mimicking actual density and
the size of human intestinal villi (Fig. 4) (Sung et al., 2011).
Caco-2 cells seeded onto the structure covered the whole struc-
ture in three weeks resembling ﬁnger-like intestinal villi cov-
ered with epithelial cells. Thus, microfabrication approaches
can be used to recapitulate the in vivo microenvironment to
construct physiologically realistic in vitro models of intestinal
villi that can improve the predictability of drug absorption
studies.
5.2. Microﬂuidic based approaches
The ﬁeld of microﬂuidics is gaining popularity in drug discov-
ery, development and personalized biomolecular diagnostics
due to their ability to provide ﬂuid ﬂow in the physiological
range. Moreover, microﬂuidics offers spatial and temporal ﬂu-
idic control in a biomimetic environment enabling long-term
cell culture and differentiation (Shaw et al., 2011). Thus,
microﬂuidics is becoming an integral part of the cell-based as-
says to predict oral drug absorption.
For realistic prediction of oral drug bioavailability, an
in vitro model should incorporate all major physiologicalFigure 4 Tissue engineering approach to create in vivo-like microen
microstructure (B) SEM image of the PDMS villi structure (ﬁgure adaobstacles to the drugs entry into systemic circulation. These
include the transport properties of the epithelium, liver
metabolism, and the vascular transport that links them. Trans-
well co-culture models have been designed to include apical
caco-2 monolayers along with hepatocytes in the basolateral
compartment (Lau et al., 2004). However, these models use
large liquid to cell ratios and are devoid of circulation of
medium. To overcome these limitations, perfused co-culture
system can be designed using microﬂuidic-based approaches.
To generate a biomimetic microenvironment for drug
absorption studies, a perfused co-culture system was designed
using microﬂuidics that enhanced cytochrome P450 (CYP)
1A1/2 activity (Choi et al., 2008). In another study, Mahler
et al. co-cultured mucous secreting HT29-MTX goblet-like
cells with Caco-2 cells to mimic intestinal cell populations
and HepG2/C3A cell line as liver cell populations. The pres-
ence of HT-29 cells resulted in Caco-2 cell layer covered with
mucus when cultured in physiologically realistic ratios (Mahler
et al., 2009a,b).
Microﬂuidics has been used to design a bioreactor system
with physiologically meaningful ﬂow conditions to study vari-
ous epithelial cell transport processes (Jang et al., 2011). Fab-
ricated a bilayer microﬂuidic system with integrated Trans
Epithelial Electrical Resistance (TEER) measurement elec-
trodes to evaluate kidney epithelial cells under physiologically
relevant ﬂuid ﬂow conditions. The apical and basolateral ﬂu-
idic chambers were connected via a transparent microporous
membrane. The top chamber contained microﬂuidic channels
to perfuse the apical surface of the cells whereas the bottom
chamber acted as a reservoir for transport across the cell layer
and provided support for the membrane. TEER electrodes
were integrated into the device to monitor cell growth and
evaluate cell–cell tight junction integrity in real time. Such
bioreactors can be easily integrated with perfused co-culture
systems that closely mimic GI epithelial barriers along with
ﬁrst pass metabolism described above (Ferrell et al., 2010).
Kimura et al. have developed a microﬂuidic device
embedded with a stirrer-based micropump to create on-chip
perfusion, and an optical ﬁber connection for on-line ﬂuores-
cence detection for drug screening and toxicity testing
(Fig. 5) (Kimura et al., 2008). In another study, a microﬂuidicvironment; (A) representation of fabrication process of crypt-like
pted from Sung et al., 2011).
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the Caco-2 culture time (Yeon and Park, 2009). In vivo perme-
abilities in the human and rat intestine are highly correlated
with those measured by the microﬂuidic device. However,
the limitation of the device is that tight cell junctions are not
formed since single cells are trapped in each micro-hole for a
short period. Consequently, this system cannot be applicable
for drugs transported through tight junctions; however, it
can still be used for drugs that are transported passively or ac-
tively with the aid of transport proteins (Yeon and Park, 2009).
5.3. Microscale cell culture analogs (lCCA)
A drug’s absorption, distribution, metabolism, and excretion
(ADME) is a result of interaction between various cells, tissues
and organs that are interconnected by vasculature. Physiolog-
ically based pharmacokinetic (PBPK) mathematical models
that describe an organism as a set of interconnected tissue or
organ compartments based on vasculature have been designed
to calculate the time-dependent distribution of a drug in vari-
ous tissues (Brown et al., 1997). An important advancement in
the ﬁeld of drug screening is to integrate multiple miniaturized
organ model systems into a single device to recapitulate the po-
tential interaction between different organs in determining the
drug’s ADME. The concept of microscale cell culture analog
(lCCA) is a physical representation of PBPK model where dif-
ferent cell types are cultured in small chambers interconnected
by ﬂuidic channels (Khamsi, 2005). Such systems offer versa-
tile in vitro models to study drug’s biotransformation, and
interaction between different tissues in determining drug’s re-
sponse (both efﬁcacy and toxicity). Fabrication and applica-
tions of macroscopic and microscopic CCAs have been
discussed in detail in recent reviews (Park and Shuler, 2003;
Esch et al., 2011).
Most of the previous work with lCCAs was done to mimic
intravenous administration of a compound as the drug was
added directly into the circulating culture medium (Viravaidya
and Shuler, 2004; Viravaidya et al., 2004). More recently, GI
tract lCCAs have been developed that include digestion, a mu-
cus layer, and physiologically realistic cell populations to
determine oral bioavailability of drugs (Fig. 6) (Mahler
et al., 2009a,b). The GI tract lCCA was used together with
a systemic lCCA to demonstrate absorption, distribution,
metabolism and toxicity of a widely used analgesic and
antipyretic drug, acetaminophen. The authors showed that
acetaminophen was absorbed and metabolized by GI cells,
then circulated to the liver cell compartment. Liver cells wereFigure 5 Representation graphic of the integrated microﬂuidic device
the AP side culture chamber. The stir-bar is driven by motor-control
Kimura et al., 2008).capable of metabolizing the drug into reactive metabolite
resulting in a dose dependent toxicity to the liver cells (Mahler
et al., 2009a,b).
Combination of microfabrication with microﬂuidics has al-
lowed precise control over microscale structures. In addition,
the ability to pattern physiologically relevant cell types, as well
as to manipulate geometry of the substrate in 3D and ﬂow
patterns/hydrodynamic shear stress in the physiological range
upon the cells takes us one step closer to creating whole-
body-on-a-chip for efﬁcient screening of drug efﬁcacy and
toxicity. Reduction in the amount of sample, spatiotemporal
ﬂuidic control, easy fabrication and reduced cost makes it
more attractive for high throughput drug screening and can
further reduce the cost of drug development if integrated earlier
in the drug development process. Potentially, such systems can
be used as an alternative to animal models in drug screening.
6. Microneedles intended for transdermal drug delivery
One alternative to oral delivery and intravenous injection is the
administration of drugs across the skin. This approach seeks to
avoid any degradation of the molecules in the gastrointestinal
tract and ﬁrst-pass effects of the liver associated with oral drug
delivery as well as the pain of intravenous injection (Polla
et al., 2000; Hadgraft and Guy, 1989; Henry et al., 1998). It
also offers the possibility to continuously control the delivery
rate over extended periods of time (Henry et al., 1998). How-
ever, conventional trans-dermal drug delivery is severely hin-
dered by the outer 10–20 mm of skin, a barrier of dead
tissue called the stratum corneum (McAllister et al., 2000).
The development of microneedles for transdermal drug deliv-
ery came about as an approach to enhance the poor permeabil-
ity of the skin by creating microscale conduits for transport
across the stratum corneum (Henry et al., 1998). The develop-
ment of microneedles that are long and robust enough to pen-
etrate this layer of skin, but short enough to avoid stimulating
nerves has the potential to make transdermal delivery of drugs
more effective (McAllister et al., 2000).
By adapting microfabrication technology, three dimen-
sional arrays of sharp-tipped microneedles can be made for
transdermal drug delivery (McAllister et al., 2000; Polla
et al., 2000; Henry et al., 1998). To fabricate microneedles, a
deep reactive ion etching process is commonly used. In this
process, a chromium masking material is deposited onto sili-
con wafers and patterned into dots that have a diameter
approximately equal to that of the base of the desired needles.
When placed in the reactive ion etcher, the wafers are exposed, Caco-2 cells are cultured only on the semipermeable membrane in
led permanent magnets beneath the device. Figure adapted from
Figure 6 Gastrointestinal tract on a chip to predict ADME after oral drug administration; (A) image of the synthesis lCCA containing
liver, kidney, bone marrow, and fat chamber. The channels connecting compartments were 100 mm deep. The other poorly and well-
perfused tissues were represented by the external de-bubbler, which was a 200 ll reservoir. (B) Image of the systemic and GI tract lCCA
experimental set-up. (C) A schematic of the ﬂow pattern in the lCCA system. (D) GI tract lCCA device and assembly. (i) The Snapwell
membrane; (ii) The Snapwell membrane being placed in between the top and bottom pieces of the GI tract lCCA; (iii) The top of the
assembled GI tract lCCA; (iv) The inlets and outlets on the apical and basolateral sides of the assembled GI tract (ﬁgure adapted from
Mahler et al., 2009a,b).
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causes a deep vertical, etch and slight lateral under etching.
The regions on the wafer that are protected by chromium re-
main and eventually form the microneedles. Etching is allowed
to proceed until the masks are undercut and fall off, leaving
behind an array of silicon spikes (Henry et al., 1998). The as-
pect ratio of the microneedles can be adjusted by simply mod-
ifying the ratio of ﬂow rates of SF6 and O2. Hollow silicon
needles can also be fabricated using deep reactive ion etching
in an inductively coupled reactive ion etcher. The deep etch
creates arrays of holes through the silicon wafer (the needle lu-
men) and the microneedles are formed by reactive ion etching
around these holes (McAllister et al., 2000).
Arrays of solid silicon microneedles have been fabricated
with individual needles measuring 150 lm in lengths, 80 lm
in diameter at the base, with a radius of curvature less than
1 lm (Henry et al., 1998). Hollow needles have also been
microfabricated with similar dimensions, but containing hol-
low bores anywhere from 5 to 70 mm in diameter, depending
on (Davies, 1997). To test their durability, the solid needles
were inserted into skin with gentle pushing, an approximate
force of 10 N. All but a few percent of the microneedles
remained intact. Even in these few needles, only the top
5–10 lm was damaged (McAllister et al., 2000; Henry et al.,
1998). Additionally the array of microneedles could also be re-
moved without additional damage and could also be reinserted
into skin multiple times.
Quantiﬁcation of transdermal transport of various mole-
cules with and without inserted microneedle arrays was usedto assess any increase in skin permeability leaving (Fig. 7).
Insertion of the microneedles increased permeability only
1000-fold because the microneedles or the silicon plate may
have blocked access to the microscopic holes (Henry et al.,
1998). When the microneedles were removed after 10 s, perme-
ability increased by 10,000 fold (Henry et al., 1998). Removal
after 1 h increased skin permeability by 25,000-fold (Henry
et al., 1998). Elevated permeability after microneedle insertion
was found to remain at approximately the same level for as
long as 5 h (Henry et al., 1998). Hollow microneedleswere also
capable of insertion into the skin without any extensive dam-
age to the microneedles or skin (McAllister et al., 2000). In
addition, the improved design of these needles increased skin
permeability further still (McAllister et al., 2000).
More recently, the original microneedle design has been
further reﬁned to provide better control over drug delivery.
Silicon micro-hypodermic needles have been fabricated in
combination with heat-controlled bubble pumps (McAllister
et al., 2000). Hollow metal microneedles have been fabricated
by deﬁning molds in epoxy and ﬁlling them by electrodeposit-
ing metal (McAllister et al., 2000). Similarly, polysilicon micro-
needles have been fabricated with reusable molds (McAllister
et al., 2000). Polysilicon microneedles are likely to be most cost
effective and have the potential to produce single use dispos-
able platforms (McAllister et al., 2000). These types of needles,
combined with a pressurized reservoir to generate a drug deliv-
ery pump, have already been incorporated into a wear able
drug infusion system to deliver insulin. Furthermore, by mod-
ifying needle dimension and design to incorporate multiple
Figure 7 (A) Scanning electron micrograph of microneedles made by reactive ion etching technique. (B) Microneedle tips inserted across
epidermis. The underside of the epidermis is shown, indicating that the microneedles penetrated across the tissue and that the tips were not
damaged. Arrows indicate some of the microneedle tips (ﬁgure adapted from Henry et al., 1998).
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micro-probes can be developed for cellular, local tissue, or sys-
temic delivery (McAllister et al., 2000).
7. Implanted microchip designed for localized drug delivery
Microfabrication technology has also created a new class of
controlled release systems for drug delivery based on program-
mable devices. These devices are particularly intriguing due to
their small size, potential for integration with microelectronics
and their ability to store and release chemicals on demand
(Santini et al., 2000). With the recent advancements in biosen-
sors and micro-machining, implanted responsive drug release
systems are becoming more plausible.
The ﬁrst experimental demonstration of a microchip with
potential application in drug delivery was described in Nature
(Santini et al., 1999). The ultimate goal was to develop a
microfabricated device devoid of moving parts, but with the
ability to store and release multiple chemical substances. The
device was fabricated by the sequential processing of a silicon
wafer using microelectronic processing techniques including
UV photolithography, chemical vapor deposition, electron
beam evaporation and reactive ion etching (Santini et al.,
1999). The experimental prototype was a 17 mm · 17 mm ·
310 lm square silicon device containing an array of 34 square
pyramidal reservoirs etched completely through the wafer
(Santini et al., 2000, 1999).
7.1. Irreversible metallic valves
The 25 nL reservoirs were sealed at one end by a thin mem-
brane of gold to serve as an anode in an electrochemical reac-
tion. One other electrode was placed on the device to serve as a
cathode. The reservoirs were ﬁlled through the open end with
the chemical to be released by either micro syringe pumps or
inkjet printing in conjunction with a computer-controlled
alignment apparatus. The open ends of the reservoirs were
then covered with a thin adhesive plastic and sealed with
waterproof epoxy (Santini et al., 2000, 1999). When submerged
in an electrolyte, ions form a soluble complex with the anodematerial in its ionic form. An applied electric potential oxidizes
the anode membrane, forming a soluble complex with the elec-
trolyte ions (Santini et al., 2000). The complex dissolves in the
electrolyte, the membrane disappears, and the chemical is re-
leased and allowed to diffuse form the reservoir. The time at
which release occurs from each individual reservoir is deter-
mined by the time at which the reservoir’s anode membrane
is removed. Each reservoir, or a group of reservoirs, may be
independently addressed by demultiplexing (Santini et al.,
2000). This allows each anode to have its own conducting path
and electric potential can be applied to any given combination
of reservoirs at any given time. However, the rate of release
from the reservoir is a function of the dissolution rate of the
materials in the reservoir and the diffusion rate of these mate-
rials out of the reservoir. Therefore, the rate of release from an
individual reservoir can be controlled by proper selection of
the materials (e.g. pure drugs, or drugs with polymers) placed
inside the reservoir. Using a material that quickly dissolves
once the reservoir is opened can be used to achieve pulsatile re-
lease whereas a material that dissolves slowly after the reser-
voir is opened can be used to achieve sustained release
(Santini et al., 2000, 1999).
7.2. Reversible polymeric valves
An alternative to the use of irreversible metallic valves is a
microchip using reversible polymeric valves. The use of ‘artiﬁ-
cial muscle’ valves in conjunction with silicon micromachined
drug release structures can render a microchip responsive to a
patient’s therapeutic requirements and deliver certain amount
of a drug in response to a biological stimulus (Low et al.,
2000). ‘Artiﬁcial muscle’ refers to a chemomechanical an actu-
ator consisting of a blend of a hydrogel and an electronically
conducting redox polymer. The redox polymer is sensitive to
pH, applied potential, and the chemical potential of its micro-
environment whereas the hydrogel provides a cross-linked net-
work of hydrophilic homo/copolymers that exhibit dramatic
swelling and shrinking upon changes in pH, solvent, tempera-
ture, electric ﬁeld, or ambient light conditions (Madou and
Florkey, 2000). By electro-polymerizing these polymers onto
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compound released or retained, via the swelling and shrinking
processes of the polymer system in response to electrochemical
actuation (Fig. 8) (Low et al., 2000).
8. Nanoporous immunoisolating biocapsules
Diabetes mellitus (DM) represents a serious medical problem.
In the US alone, it is the third leading cause of death. While
the majority of patients have type-2 diabetes, about 10% of
all patients diagnosed with DM are insulin-dependent (type
1). In both cases, disease is caused by decreased circulating
concentrations of insulin and decreased response of peripheral
tissue to insulin (insulin resistance).
The disease manifests itself as hyperglycaemia. Insulin re-
mains the mainstay of virtually all type-1 DM and many
type-2 DM patients and in most cases is administered subcuta-
neously. However, the kinetics of insulin administered by this
route does not mimic the normal rapid rise and decline of insu-
lin secretion in response to ingested nutrients.
Efforts to address the short-comings of current subcutane-
ous administration of insulin, including the use of complex
multi-dose regimens, have led to the development of other dos-
age forms and routes of administration such as ‘needleless’
injectors, constant infusion pumps, and inhaled insulin. These
newer approaches still suffer from the same general issue
plaguing current subcutaneous administration.
8.1. Allotransplantation
A potentially useful approach, which has proven effective in
only a handful of cases, is the allotransplantation of islets or
whole pancreases from a suitable human donor into a diabetic
recipient. Researchers in Canada recently reported successful
transplantation of islet cells in type 1 DM patients (Davies,
1997). Although the potential complications of immunosup-
pressive therapy were reduced by avoiding the use of glucocor-
ticoids, each transplant required two harvestings of islet cells
from organ donors. Moreover recipients are still required to
take immune suppressing drugs for the rest of their lives. TheseFigure 8 (A) A Ag/AgCl and IrO valve electrode in the same midrom
SEM micrograph of ‘artiﬁcial muscle’ grown on TEM gold grid co
reservoir. (Figure adapted from Low et al., 2000).immunosuppressive drugs are toxic and have potential adverse
side effects, including cancer. For this reason, an islet or pan-
creas allotransplant is normally carried out only in conjunction
with a kidney transplant, for which immunosuppression is re-
quired in any case.
Because of the toxicity of immune suppressing drugs, and
the shortage of organ donors, islet and pancreas allotransplan-
tation appears to hold limited promise as a cure for diabetes. A
method then is required to sequester the islets from the body’s
immune system which is able to recognize and reject these
xenogeneic cell grafts. For the past 20 years, investigators have
focused on a range of microencapsulation methods most com-
monly involving sodium alginate and another polycationic
substance such as polylysine. These materials have been used
in an attempt to create a semipermeable membrane capable
of blocking immune molecules such as IgG, cytokines, and
cell-secreted antigens from reaching the encapsulated xenoge-
neic islet cells while allowing glucose and insulin to freely dif-
fuse through the barrier (Lanza and Cooper, 1999). However,
this approach has proven generally unsuccessful due to
mechanical rupture of the membrane, biochemical instability,
incompatibility with islet cell heterogeneity, and broad pore
size distributions (Lanza and Cooper, 1999; Lacy et al.,
1991; Lanza et al., 1996). When the barrier between the xeno-
geneic cells and the external bioenvironment is compromised,
these foreign cells are subject to various endogenous cells
and antibodies as well as complement and a host of cytokines
such as tumor necrosis factor, all of which can inﬂict cell dam-
age. As a result, the use of polymeric microcapsules for allo-
transplantation has been unsuccessful clinically in the
absence of immunosuppression (Lanza and Cooper, 1999;
Lacy et al., 1991; Lanza et al., 1996).
8.2. Biocapsule design
Microfabrication techniques have been applied to create a bio-
capsule for effective immunoisolation of transplanted islet cells
for treatment of diabetes (Desai et al., 1998). The fabrication
of nanochannels in the membrane structure consists of two
steps: (1) surface micromachining nanochannels in a thin ﬁlmachined drug delivery cavity. Both electrodes are 30,330 mm. (B) x
ated with poly-HEMA in holes (38.5 mm–338.5 mm) of a drug
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by etching away the bulk of the silicon wafer underneath the
membrane. These nanopore membranes (Fig. 9A) are designed
to allow the permeability of glucose, insulin, and other meta-
bolically active products, while at the same time, preventing
the passage of cytotoxic cells, macrophages, antibodies, and
complement. The membranes are bonded to a capsule that
houses the pancreatic islet cells. Because the difference in the
size of insulin, which must be able to pass freely through the
pores and the size of IgG immunoglobulins, which must be ex-
cluded, is only a matter of a few nanometers, the highly uni-
form pore size distribution provided by micromachine
membranes is essential for effective immunoisolation and ther-
apeutic effect.
Control of pore sizes in the tens of nanometers has recently
been suggested as probably the most realistic way to achieve
immuneisolation (Brissova et al., 1998; Wang et al., 1997).
The use of unconventional biomaterials such as silicon and sil-
icon dioxide provides a means to encapsulate pancreatic islet
cells in devices that are thermally, chemically, and mechani-
cally stable and retrievable. It is also expected that improved
dynamic response of islets can be obtained due to the limited
membranes thickness (Fig. 9B) compared with the thickness
of conventional polymeric membranes prepared from alginate
and polylysine (100–200 lm) (Brissova et al., 1998). It is cru-
cial that rapid secretion kinetics, particularly in the ﬁrst phase
of insulin release, be maintained over time to provide physio-
logic feedback control of blood glucose concentrations.
Another key feature of an implanted biocapsule system is
the role of neovascularization. The membranes proposed for
testing have outer openings of 2 by 2 mm while the inner dif-
fusion channels have a pore size of between 10 and 30 nm.
Studies have shown that neovascularization at the mem-
brane–tissue interface occurs in membranes having pore sizes
large enough to allow complete penetration by host cells
(0.8–8 mm) (Brissova et al., 1998). Thus, it is expected that
neovascularization can occur at the large openings while not
penetrating into the nanometer pores. This phenomenon has
two key advantages: (1) the ability to rapidly deliver insulin
into the blood stream through new blood vessel growth while
(2) limiting pore clogging or fouling.Figure 9 (A) Micrograph of a biocapsule membrane with 24.5 nm
(Figure adapted from Brissova et al., 1998).9. Applications of biomems devices in analytical techniques
Clinical medicine greatly beneﬁts from MEMS as lab-on-chip
technology as it suites for drug tests, tests for observing pan-
demics, glucose monitoring, diabetic control, diagnosis of dis-
eases and numerous other tests. Lab-on-chip devices enhance
numerous biomedical tests that entail mixing, analysis and sep-
aration of samples, which usually consist of cell suspensions,
nucleic acids, proteins, etc. Analytical, electrical, or optical
detection methods are possible. The electrical detection meth-
ods depend exclusively on the polar properties of the molecules
of the liquid samples. For example, carbon dioxide levels, oxy-
gen levels, or pH values can be measured electrochemically. On
the contrary, most analytical or optical techniques require
labelling, which entails chemo-luminescence, ﬂuorescence, or
radioactive markers. Most separation methods of lab-on-chip
systems are miniaturized approaches of larger ones. There
are diverse screening methods, which offer high sample
throughput, whereas other methods offer reliability and preci-
sion. The separation of biomolecules, cells, or nanoparticles
can be managed by transportation methods, which are based
on the charge and size of the substances. These transportation
methods can be the following ones:
a. Hydrodynamic manipulation, which employs hydrody-
namic pressure (Takagi et al., 2005; Yamada and Seki,
2005; Jaggi et al., 2007; Choi et al., 2007)
b. Electrical manipulation which transports electrolytes,
suspensions of particles or cells, or entire aqueous vol-
umes like droplets, via the use of electrokinetic mecha-
nisms such as electrophoresis (Zhang and Manz, 2003),
dielectrophoresis (Jones et al., 2002, 2003) and electrow-
etting (Pollack et al., 2000, 2002; Washizu, 1998; Moon
et al., 2002)
c. Magnetophoresis that employs magnetic ﬁelds in con-
junction with magnetic nanoparticles suspended in the
samples (Pamme and Wilhelm, 2006)
Optical manipulation that employs laser-light pressure
which moves nanoparticles or tiny droplets (MacDonald
et al., 2003; Pamme, 2007); alternatively, light actuation canpores, (B) Insulin secretory proﬁle through differing pore sizes.
Biomedical microelectromechanical systems (BioMEMS) 15alter locally the degree of hydrophobicity of a surface and con-
sequently direct aqueous volumes via hydrophilic routes.
Electrical and mechanical micropumps are largely em-
ployed in microﬂuidic manipulation (Laser and Santiago,
2004). Electric micropumps utilize electrokinetics (Gascoyne
and Vykoukal, 2002), piezoelectric (Van Lintel et al., 1988;
Nisar et al., 2008) or magnetohydrodynamics (Zhong et al.,
2002). While mechanical micropumps utilize hydrodynamic
pressure (Xu et al., 2001), thermal expansion (Yokoyama
et al., 2004), osmotic pressure (Salimi-Moosavi et al., 1997),
or other transducer or induced forces. Electrocapillary, an
important electrokinetic pumping mechanism, boosted the
development of lab-on-chip devices (Harrison et al., 1992; Li
and Harrison, 1997; Manz et al., 1991). This achievement
caused the realization of miniaturized analytical instruments,
namely on-chip chromatographic systems (Terry et al., 1979).
Other pumping mechanisms employ thermal gradients, or
magnetophoresis. Fluidic lab-on-chip devices can facilitate cell
screening (Oh et al., 2006; Choi et al., 2007; Tan et al., 2006).
This works on the basis of forcing cells into speciﬁc stream-
lines, separates them by size, and drives them into speciﬁc out-
lets (Yamada et al., 2004). This ﬁnds applications in blood cell
separation, where erythrocytes ﬂow right in the centre of a
microcapillary and the leukocytes, due to their differing mass,
pursue streamlines along the capillary wall (Jaggi et al., 2007;
Shevkoplyas et al., 2005). Besides hydrodynamic separation,
microvalves can sort suspensions of cells or nanoparticles, usu-
ally in conjunction with electrokinetic actuation methods (Go-
mez-Sjoberg et al., 2007; Nevill et al., 2007; Melin and Quake,
2007). Electrically actuated microvalves are made of electroac-
tive elastomers or piezoelectrics, which can be embedded easily
in ﬂuidic chips. Piezoelectric micropumps are activated when
voltage applies on a piezoelectric material causing expansion.
The expansion can be several micrometres, but in the micro-
scale this causes signiﬁcant pressure, which pushes the ﬂuid
adequately. Magnetically actuated microvalves also exist,
made of magnetically inductive materials. The magnetic actu-
ation ﬁeld can be produced on-chip by means of current pat-
terns, integrated on the chip. Lab-on-chip devices are
efﬁcient in mixing samples in a controllable and precise man-
ner due to the use of tiny liquid volumes. Examples of mixers
include distributive mixers, static mixers, T-junction mixers
and vortex mixers. Active mixers consume power in order to
increase the interfacial area between the mixing ﬂuids.
Examples of active mixers include electrokinetic mixers, cha-
otic advection mixers and magnetically driven mixers. Passive
mixing can be achieved in microchannels with structures called
twists that cause turbulence. Some mixers are more efﬁcient at
faster ﬂow rates, whereas others work more efﬁciently at
slower ﬂow rates (Squires and Quake, 2005).
Temperature control is important in microﬂuidic devices.
Temperature gradients can be generated inside microﬂuidic
channels by means of miniaturized heating elements, such as
heat exchangers, heaters or coolers (Talary et al., 1998). The
efﬁciency of micro-heat exchangers depends on their ability
to regulate the temperature of the transported ﬂuid, in con-
junction with reservoirs that buffer rapid changes of tempera-
ture. The micro-heaters are assembled in the form of coils. Due
to the inherently small dimensions of the microﬂuidic devices,
the thermal coupling between a micro-heater and a reservoir is
very efﬁcient. Coolers can be made out of heatsinks that induct
the heat to the environment. The combination of small ﬂuidicvolumes and the precision of the heatsinks allow cooling to
ambient temperature with ease. Repeatable temperature cycles
are essential in the process for nucleic acid ampliﬁcation and
ﬁnd application in the polymerase chain reaction (PCR) ar-
rays-on-chips (Talary et al., 1998; Kopp et al., 1999; Wildinga
et al., 1998; Shoffner et al., 1996; Cheng et al., 1996). PCR rep-
licates small amounts of nucleic acids into large amounts. PCR
involves a three-step thermal cycle that promotes the replica-
tion: heating (90–95 C), cooling (50 C), and slight warming
(60–70 C). PCR chips include various temperature zones
whose beneﬁt is that the cycle time no longer relies on the time
required to heat or cool the sample. The beneﬁt of performing
PCR in microﬂuidic chips is due to the very small liquid vol-
umes used, for which temperature homogeneity and diffusion
efﬁciency are higher in comparison with ordinary laboratory
vessels. However, thermal cycles may induce undesirable ef-
fects, especially regarding evaporation and bubble formation.
The droplet-based biochips eliminate most of these defects
during PCR processes due to the isolation of the droplets by
a second phase oleic ﬂuid (Wang et al., 2005; Beer et al.,
2007). Fully automated PCR biochips that contain mixers,
heaters, and microarray sensors are capable of performing
sequential functions like hybridization, preconcentration, puri-
ﬁcation, lysis, and electrochemical assessment of complex bio-
logical solutions (Liu et al., 2004). In bio-analysis, biosensors,
integrated in microﬂuidic devices, offer possibilities for electro-
chemical or optical analysis of samples. Enzyme-based electro-
chemical biosensors can measure oxygen consumption or pH
production by means of enzymatic reactions. The enzymes
catalyse the reactions of the analytes and the sensor measures
the products (Urban, 2009). In the ﬁeld of bioanalytical sepa-
ration, the capillary chromatographic chips adopt ﬂuorescent
polystyrene nanoparticles or labelled macromolecules to en-
hance cell or protein separation by image recognition (Kutter,
2000; Chmela and Tijssen, 2002; Blom et al., 2002). In analogy,
the ion exchange chromatographic chips separate electrokinet-
ically analytes such as polar molecules, proteins, nucleotides
and amino acids according to their ionic charge. Genomic re-
search requires analysis, which can be utilized by means of
specialized ﬂuidic chips called microarrays, which are arrange-
ments of open planar arrays that each contains thousands of
speciﬁc oligonucleotides, covalently bonded on glass or silicon
substrate (Niemeyer and Blohm, 1999; Blohm and Guiseppi-
Elie, 2001; Pirrung, 2002; Jung, 2002). These oligonucleotides
function as probes, which hybridize the DNA fragments that
contact the microarray, by forming hydrogen bonds between
the DNA fragments and the complementary nucleotide base
pairs of each probe. A microarray can accomplish many geno-
type tests in parallel. The detection method in microarray chips
is based on microscopy analysis via the use of ﬂuorophore or
chemoluminescence labels that determine abundance of nucleic
acid sequences. The lab-on-chip microarrays can be distin-
guished between cDNA-microarrays and oligonucleotide-
microarrays. The latter can perform genotyping and rese-
quencing (Saliterman, 2005). The microarray chips can be em-
ployed in nucleic acid analysis, which includes DNA extraction
and puriﬁcation, ampliﬁcation, hybridization, sequencing,
gene expression analysis, genotyping and DNA separation.
Moreover, microarrays can recombine nucleotide fragments
by employing endonucleases to cleave and rebind the frag-
ments with DNA ligase enzymes. Fluorescence microscopy is
mainly employed in microarrays because of its challenging
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concentrations of Pico-moles. Detection sensitivity of Pico-
moles is appropriate in most applications that require high sen-
sitivity, such as DNA sequencing and many immunoassays
(Fan and Ricco, 2006). There are great potential applications
of microarray chips in biotechnology as well as of DNA-in-
spired lab-on chips in nanotechnology (Wagenknecht, 2008).
The oxidative type of DNA-mediated charge transport has sig-
niﬁcant results in mutagenesis, apoptosis, or cancer studies. On
the other hand, excess electron transport plays a growing role
in the development of electrochemical DNA chips for the
detection of DNA base mutations (Drummond et al., 2003).
Knowledge about excess electron transport in DNA has poten-
tials for nanotechnological applications, such as supramolecu-
lar electronics. In this ﬁeld, the research focuses on the role of
DNA as supramolecule that features important properties for
nanowires (Porath et al., 2004).
Lab-on-chip devices support cell detection by means of cap-
illary electrophoresis, electroporation, cytometry or electrical
impedance. The cells can be cultivated within aqueous mic-
roreactors inside the chips (Nevill et al., 2007; Melin and
Quake, 2007; Martin et al., 2003). With lab-on chip devices
one can measure accurately chemical stimuli on cells, as cellu-
lar signals are weak and not easily detected with conventional
analytical methods. Cytometers allows cell counting and anal-
ysis of cellular parameters like size distribution or growth rate.
Cytometry commonly employs electrical impedance methods
(Sun et al., 2007), but also employs ﬂuorescence microscopy;
however, ﬂuorescence microscopy requires cell labelling with
dyes or ﬂuorescent nanoparticles and external optical appara-
tuses, such as optical ﬁbres and illuminators (Fu et al., 1999).
Other electrokinetic methods rely on contactless conductivity
detection of organic ions or electrolytes where typically two
on-chips embedded tubular electrodes, away from each other,
measure changes of the ohmic resistance of the solution that
ﬂows inside the microﬂuidic channel (Wang and Pumera,
2002; Laugere et al., 2003; Pumera et al., 2002; Lee et al.,
2006) Capillary electrophoresis performs electroseparation of
the ionic compounds, based on the size tocharge ratio of the
ions, which are transported electrokinetically in the carrier li-
quid. The electrocapillary forces drag the ions into the capil-
lary channel while the ﬂuidic sample approaches the inlet of
the microchannel (Gorbatsova et al., 2009; Abad-Villar
and Kuban, 2005). Capillary electrophoresis is capable of
separating particulate substances like cells, amino acids,
proteins, peptides, mitochondria, or bacteria (Cabrera and
Yager, 2001). In microﬂuidic channels the surface-to-volume
increases signiﬁcantly due to reduced dimensions, and electro-
phoresis force becomes more efﬁcient due to the shortening of
the distance. In capillary electrophoresis devices the electric
ﬁelds range to some hundreds V/cm with pulse durations of
milliseconds. Capillary electrophoresis separation is fast and
robust and high throughput can be obtained. Electroporation
is an electrical method that accesses the interior of cells. Apply-
ing short and intense electric pulses increases the conductivity
and transiently permeabilizes the lipid membrane of a cell and
introduces substances into the cytoplasm. Electroporation is
used for inserting drugs or genes into cells and is highly
efﬁcient when performed in vitro in lab-on-chip devices (Lu
et al., 2005). Electrokinetic manipulation of suspended
particles by means of electric ﬁelds is widely used in lab-
on-chip devices for in vitro separation of particles or cells(Li et al., 2007). Dielectrophoresis manipulates and separates
cells, beads or nanoparticles by means of inhomogeneous elec-
tric ﬁelds that can be produced with electrodes of speciﬁc
shapes (Jones et al., 2003; Jones, 2002). The cells can be col-
lected or directed away from the electrodes under the inﬂuence
of the dielectrophoresis force, which is directed towards the
ﬁeld gradient, and originates from the permittivity difference
between the carrier ﬂuid and cells (Huang and Pethig, 1991).
The possibility of using dielectrophoresis for in vitro separa-
tion of blood cells, based on their conductivity characteristics,
can automate partition of white blood cells from erythrocytes.
Several human cancer cells have been successfully studied and
dielectrophoretically sorted (Gascoyne et al., 1997; Wang
et al., 1997; Cen et al., 2004). Dielectrophoresis can further
measure dielectric differences of cells or particles by means
of electro-rotational spectra (Jones, 1995). Cancerous cells
are different from healthy erythrocytes and lymphocytes. Their
dielectric diversiﬁcation can be exploited for removing
metastatic cancer cells from healthy blood cells. Other electro-
kinetic means with growing applications in lab-on-chips tech-
nology is electro-osmotic ﬂow, a coulomb effect that results
in transportation of ions of an electric double layer (Kirby,
2010; Cahill et al., 2004), and its reverse effect, streaming
potential, that is induced voltage on an electrode due to the
ﬂowing motion of counter-ions of an electric double layer
(Chun et al., 1996).
Today, magnetic separation devices are available and mag-
netic cell separation offers diagnostic and therapeutic values
(Estes et al., 2009). Magnetophoretic sorters can capture cells
that are bonded with magnetic beads, or nanoparticle aggre-
gates, and force them ﬂow into the carrier ﬂuid with increased
selectivity (Pamme and Wilhelm, 2006; Gijs, 2004). Moreover,
magnetic nanoparticles can be used to destruct targeted cells
by penetration, or to release carried drug into the cell’s cyto-
plasm (Ogiue-Ikeda et al., 2003). The magnetic ﬁeld can be
generated by current patterns on the chip. An important
advantage of magnetic actuators in comparison with the elec-
tric ones is due to the magnitude of the magnetic driving force
that is signiﬁcantly larger in comparison to electrokinetic
forces. This highly improves the control of the liquid ﬂow.
The possibility of incorporating magnetic nanoparticles into
cells as inert tracers for cell monitoring, allows measuring cyto-
skeleton associated cell functions (Valberg and Butler, 1987;
Wang et al., 1993). Within cytoplasm the magnetic nanoparti-
cles may equilibrate, but intracellular transports disorient the
magnetic nanoparticles resulting in the decay of magnetization
which can be recorded by magneto-impedimetric sensor,
embedded in the chip. Magnetic actuators can transport aque-
ous droplets that enclose magnetic nanoparticles (Egatz-go´mez
et al., 2006). Under the inﬂuence of the magnetic ﬁeld the mag-
netic nanoparticles can drag the droplet and execute all the
usual microﬂuidic operations such as displacement, merging,
mixing and separation (Lehmann et al., 2006).10. Conclusion
Microfabrication techniques have been adapted as BioMEMS
to create physiologically relevant materials and devices that
mimic the scale cells experience in vivo and have found wide
biomedical applications, including drug delivery, tissue engi-
neering and analytical techniques. BioMEMS devices must
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reliable and useable. The race to ﬁnd effective diagnostic and
the therapeutic tools is under way, as BioMEMS are getting
closer to the clinical application of intelligent drug delivery de-
vices and signiﬁcantly enhanced the analytical devices ever be-
fore. Though a danger exist in proclaiming this technology a
panacea for a large portion of biomedical problems such
assertions are doomed to failure; entrenched, mature
conventional technology is meant to supplement this estab-
lished technologies.References
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